Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology, Inc., a U.S.-based developer of novel cancer therapies and a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., has a diversified preclinical and late-stage pipeline spanning multiple areas, including oncogenic pathways, survival mechanisms, and novel protein interactions, aiming to address unmet clinical needs in oncology.